This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Iwadate, Y. Articles by Tagawa, M. Search for Related Content PubMed PubMed Citation Articles by Iwadate, Y. Articles by Tagawa, M.

Induction of Immunity in Peripheral Tissues Combined with Intracerebral Transplantation of Interleukin-2-producing Cells Eliminates Established Brain Tumors¹

Department of Neurological Surgery, Graduate School of Medicine, Chiba University, Chiba 260-8670 [Y. I., A. Y.], and Divisions of Diagnostic Imaging [Y. S.], Biochemistry [S. S.], and Pathology [M. T.], Chiba Cancer Center Hospital and Research Institute, Chiba 260-8717 Japan

Cytokine gene therapy for the induction of potent immune responses against central nervous system tumors has proven to have significant potential. However, this strategy needs improvement in the process of antigen presentation and/or insufficient recruitment of immunocompetent cells to achieve successful eradication of established brain tumors. We investigated the therapeutic potential of induced systemic immunity in peripheral tissues combined with interleukin-2 (IL-2) production in the vicinity of brain tumors to treat established brain tumors. Sequential magnetic resonance image monitoring showed that the combinatory therapy consisting of intracerebral (i.c.) transplantation of IL-2-producing rat gliosarcoma 9L (9L/IL-2) cells and s.c. vaccination using irradiated 9L or 9L/IL-2 cells could cure 9L-bearing rats, whereas either the i.c. injection of 9L/IL-2 cells or the s.c. vaccination produced little or marginal antitumor effects, respectively. Xenogeneic murine neuroblastoma cells secreting IL-2 could substitute for 9L/IL-2 cells, producing significant antitumor effects in the vaccinated rats. Tumor-specific cytotoxic activity was induced in the vaccinated rats but not fully in the rats treated only with i.c. injection of 9L/IL-2 cells. Immunohistochemical analysis revealed that a number of CD4⁺ and CD8⁺ T cells infiltrated into the brain tumors which were treated with the combinatory therapy. The level of cell infiltration was similar to that found in s.c. 9L/IL-2 tumors which were subsequently rejected. In contrast, the brain tumors treated with either i.c. transplantation of 9L/IL-2 cells or the s.c. vaccination showed only moderate infiltration of T cells. The combinatory strategy, i.c. grafting of IL-2-producing cells, and s.c. immunization of irradiated whole tumor cell vaccine, is, thus, effective for recruiting activated T cells into the brain tumor site and could be a potential therapy for brain tumors.

This article has been cited by other articles:

				S. A. Schwartz, R. J. Weil, R. C. Thompson, Y. Shyr, J. H. Moore, S. A. Toms, M. D. Johnson, and R. M. Caprioli Proteomic-Based Prognosis of Brain Tumor Patients Using Direct-Tissue Matrix-Assisted Laser Desorption Ionization Mass Spectrometry Cancer Res., September 1, 2005; 65(17): 7674 - 7681. [Abstract] [Full Text] [PDF]

				Y. Iwadate, M. Inoue, T. Saegusa, Y. Tokusumi, H. Kinoh, M. Hasegawa, M. Tagawa, A. Yamaura, and H. Shimada Recombinant Sendai Virus Vector Induces Complete Remission of Established Brain Tumors through Efficient Interleukin-2 Gene Transfer in Vaccinated Rats Clin. Cancer Res., May 15, 2005; 11(10): 3821 - 3827. [Abstract] [Full Text] [PDF]

				S. O. Rahaman, M. A. Vogelbaum, and S. J. Haque Aberrant Stat3 Signaling by Interleukin-4 in Malignant Glioma Cells: Involvement of IL-13R{alpha}2 Cancer Res., April 1, 2005; 65(7): 2956 - 2963. [Abstract] [Full Text] [PDF]